Mayo Clinic’s AI approach shows promise for diagnosing and assessing the risk of meningiomas

A study from Mayo Clinic demonstrated that artificial intelligence (AI) can aid with the diagnosis and risk analysis of meningiomas, offering another option for those who don’t have easy access to genetic testing. The findings are reported in a release and could lead to more accessible, personalized care.

The researchers trained AI to “extract molecular and prognostic information from standard hematoxylin and eosin, or H&E, slides” with real data from 672 patients. The models successfully detected meningiomas and offered insights into patients’ risk of recurrence. Additionally, the “AI-based predictions remained useful even after accounting for traditional clinical factors.”

The researchers are calling for more studies but are hopeful that this approach will help improve patient outcomes.